Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.

ABSTRACT:

Background

Recently, a new coronavirus spreads rapidly throughout the countries and resulted in a worldwide epidemic. Interferons have direct antiviral and immunomodulatory effects. Antiviral effects may include inhibition of viral replication, protein synthesis, virus maturation, or virus release from infected cells. Previous studies have shown that some coronaviruses are susceptible to interferons. The aim of this study was to evaluate the therapeutic effects of IFN-β-1a administration in COVID-19.

Methods

In this prospective non-controlled trial, 20 patients included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All patients received conventional therapy including Hydroxychloroquine, and lopinavir/ritonavir. Demographic data, cli

SUBMITTER: Dastan F 

PROVIDER: S-EPMC7275997 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature